Relypsa (Relypsa) Total Inventories : $31.88 Mil (As of Jun. 2016)

View and export this data going back to 2013. Start your Free Trial

What is Relypsa Total Inventories?

Relypsa's total inventories for the quarter that ended in Jun. 2016 was $31.88 Mil. Relypsa's average total inventories from the quarter that ended in Mar. 2016 to the quarter that ended in Jun. 2016 was $28.38 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Relypsa's Net-Net Working Capital per share for the quarter that ended in Jun. 2016 was $1.43.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Relypsa's Days Inventory for the three months ended in Jun. 2016 was 10,114.85.

Inventory Turnover measures how fast the company turns over its inventory within a year. Relypsa's Inventory Turnover for the quarter that ended in Jun. 2016 was 0.01.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Relypsa's Inventory-to-Revenue for the quarter that ended in Jun. 2016 was 5.44.

Relypsa Total Inventories Historical Data

The historical data trend for Relypsa's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa Total Inventories Chart

Relypsa Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Total Inventories

8.85

Relypsa Quarterly Data
	Dec11	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Total Inventories	Get a 7-Day Free Trial												-	-	8.85	24.87	31.88

Relypsa Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Relypsa (NAS:RLYP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Relypsa's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2016 is

	Net-Net Working Capital Per Share (Q: Jun. 2016 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(257.726	+	0.75 * 1.338	+	0.5 * 31.881	-	210.657
-	0	-	0)	/	44.826
=	1.43

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Relypsa's Days Inventory for the three months ended in Jun. 2016 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2016 )	/	Cost of Goods Sold (Q: Jun. 2016 )	*	Days in Period
	=	28.377	/	0.256	*	365 / 4
	=	10,114.85

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Relypsa's Inventory Turnover for the quarter that ended in Jun. 2016 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2016 )	/	Average Total Inventories (Q: Jun. 2016 )
	=	0.256	/	28.377
	=	0.01

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Relypsa's Inventory to Revenue for the quarter that ended in Jun. 2016 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2016 )	/	Revenue (Q: Jun. 2016 )
	=	28.377	/	5.221
	=	5.44

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Relypsa Total Inventories Related Terms

Thank you for viewing the detailed overview of Relypsa's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Relypsa (Relypsa) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.relypsa.com

Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Executives

Ronald A. Krasnow	officer: See Remarks	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball	officer: Chief Financial Officer & SVP	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J	director	33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings	director	61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl	officer: SVP, Chief Technology Officer	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland	officer: SVP & Chief Commercial Officer	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley	director	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi • 10-26-2015